Kohl's Corporation vs GeneDx Holdings Corp — how do they compare? Kohl's Corporation trades at $19.24 (market cap $2.10B), while GeneDx Holdings Corp trades at $81.32 (market cap $2.44B). The key difference: GeneDx Holdings Corp is the larger of the two by market cap, and Kohl's Corporation pays a 2.7% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| KSS | WGS | |
|---|---|---|
Market Cap | $2.10B | $2.44B |
Sector | Consumer Cyclical | Technology |
52-Week High | $24.71 | $167.51 |
52-Week Low | $11.72 | $34.51 |
Enterprise Value | $8.20B | $2.48B |
Dividend Yield | 2.7% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.
Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.
Trailing returns across standard periods
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →